Information Provided By: 
Fly News Breaks for March 4, 2019
IMMU
Mar 4, 2019 | 07:11 EDT
H.C. Wainwright analyst Raghuram Selvaraju started Immunomedics with a Buy rating and $28 price target. IMMU-132 is a pipeline in a single asset, with applicability across a range of solid tumor types known to express trop-2, Selvaraju tells investors in a research note. The analyst believes IMMU-132 would be particularly applicable in second- and third-line triple-negative breast cancer. The drug's efficacy profile should only improve as it migrates towards earlier settings in the treatment continuum, says Selvaraju.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
